Document is current

Article History

Received: 9 February 2023

Accepted: 17 July 2023

First Online: 27 July 2023

Declarations

:

: The IBSEN III study (Clinical Trials ID: NCT02727959, first trial registration date 05/04/2016) was approved by the South-East Regional Committee for Medical and Health Research Ethics (Ref. 2015/946-3), and all patients signed written informed consent forms before participating in the study. The study was performed in accordance with the ethical guidelines of the Declaration of Helsinki.

: Not applicable.

: IJ, MCS, SL, CL, BO, GHH, TA, M-BB, PR, L-PJJ, and RO declare no competing interest. VAK received speaker fees from Janssen-Cilag AS, consultant fees and scientific board fees from Takeda AS, and advisory board fees from Tillotts Pharma AG. MLH received speaker fees from Galapagos, Ferring, BMS, Janssen, AbbVie, Meda, Tillotts, and Takeda; is on the advisory boards of Takeda, Galapagos, BMS, and AbbVie; and initiated research grants from Takeda, Pfizer, Tillotts, and Ferring. VS received grants from Takeda AS. TED has served as a speaker, consultant, or advisory board member for AbbVie, Ferring, Pfizer, Pharmacosmos, Tillotts, and Vifor Pharma. Furthermore, he has received ounrestricted research grants from AbbVie and Pharmacosmos. SOF received personal fees from Takeda, Galapagos, Jansen-Cilag, AbbVie, Pharmacosmos, Norgine, and Bristol-Myers-Squibb outside the submitted work.